AbbVie Inc.
As of Oct 23, 2026 close
- Market cap
- $505.87B
- P/E (TTM)
- 80.17
- Forward P/E
- 47.79
- Dividend yield
- 2.43%
- 52-week range
- $190.75$291.40
- Volume (live)
- -
- Avg. volume (3M)
- 4.82M
AbbVie (ABBV) Stock Price & Financial Analysis
AbbVie Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $282.30 - $286.77 |
|---|---|
| 52-Week High | $291.40 |
| 52-Week Low | $190.75 |
| Open | $284.58 |
| Volume (last close) | 4.63M |
| Average Volume (3M) | 4.82M |
| Revenue (TTM) | 64.39B |
|---|---|
| Net Income (TTM) | 6.31B |
| Free Cash Flow (TTM) | 18.21B |
| EPS (TTM) | $3.56 |
| Profit Margin | 9.80% |
| Operating Margin | 28.17% |
| Annual Dividend | $6.92 |
|---|---|
| Dividend Yield | 2.43% |
| Payout Ratio | 194.44% |
| Last Dividend Ex-Date | Oct 15, 2026 |
| Market Cap | 505.87B |
|---|---|
| Shares Outstanding | 1.77B |
| P/E Ratio (TTM) | 80.17 |
| Forward P/E | 47.79 |
| Price to Sales (P/S) | 7.86 |
| Price to Book (P/B) | -85.23 |
| EV/EBITDA | 19.99 |
| 50-Day MA | $264.01 |
|---|---|
| 200-Day MA | $234.52 |
| 1-Year Change | +24.95% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
AbbVie at a Glance
As of the Oct 23, 2026 close, AbbVie (ABBV) has a market capitalization of $505.87B. The stock trades at 80.2× trailing earnings, 47.8× forward earnings and 7.9× sales. Over the trailing twelve months it earned $6.31B on revenue of $64.39B (a 9.8% profit margin) and generated $18.21B of free cash flow. Revenue grew 10.4% year over year.
As of its latest reported balance sheet, it holds $6.57B in cash and securities against $70.82B of debt, a net debt position of $64.25B.
AbbVie pays a quarterly dividend totaling $6.92 per share a year, a 2.43% yield at the Oct 23, 2026 close, with a 194% payout ratio and 12 consecutive years of dividend increases.
The share price is up 24.9% over the past year. At $285.64 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $190.75 to $291.40, above its 200-day moving average of $234.52.
Based on 32 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $293.29, 2.7% above the Oct 23, 2026 close.
Frequently Asked Questions About AbbVie
What is the current stock price for ABBV?
As of the Oct 23, 2026 close, ABBV stock trades at $285.64. The 52-week range is $190.75–$291.40, with a day range of $282.30–$286.77.
What is the P/E ratio for ABBV?
As of the Oct 23, 2026 close, AbbVie's trailing twelve-month (TTM) P/E ratio is 80.2, meaning investors pay $80.2 for every $1 of annual earnings. The forward P/E is 47.8, reflecting analyst expectations for future earnings. AbbVie operates in the Healthcare sector.
Does ABBV pay dividends?
Yes, AbbVie pays a 2.43% annual dividend yield as of the Oct 23, 2026 close ($6.92 per share a year). The trailing twelve-month payout ratio is 194.4%. The most recent ex-dividend date was October 15, 2026.
What do analysts recommend for ABBV?
Based on ratings from 32 professional analysts over the last 90 days, the consensus for ABBV is Buy. The average 12-month price target is $293.29, a 2.7% upside from the Oct 23, 2026 close of $285.64.
What is the market cap of ABBV?
As of the Oct 23, 2026 close, AbbVie's market capitalization is $505.87B, classifying it as a mega-cap company. AbbVie operates in the Healthcare sector within the Drug Manufacturers - General industry.